Company intelligence / Profile preview

EMBTP

Berlin, Berlin, Germanymr.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

emp BIOTECH manufactures high-quality reagents, solvents mixtures, fine chemicals, labeling kits, cell culture transfection agents, columns/resins for biomolecule purification and solid phases used in oligonucleotide synthesis. Their products are used from early-stage R&D to large-scale manufacturing by pharmaceutical/biotech companies developing cell-based immunotherapies, vaccines and other advanced therapies. They do not have their own clinical pipeline but enable global science innovation through their products.

Modalities: Oligonucleotide synthesis reagentsLabeling kits
Industry: Chemicals & Materials

Beyond the preview

Go deeper on EMBTP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMBTP.

Explore the full profile